Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.

Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?

Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.

Researchers at Washington University School of Medicine in St. Louis found further evidence that microglia are the key link between the accumulation of abnormal proteins, including beta-amyloid and tau, in the brain and the actual brain damage observed in Alzheimer’s patients.

Doctors studying lung tissue from people with vaping-related injuries have ruled out one diagnosis as a probable explanation of how vaping harms the lungs, further deepening the mystery over the exact cause of hundreds of illnesses in the United States.

Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.

Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.

Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine.

Top 10 Pipelines To Watch: 2019 Annual Report

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.